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Increased flux through the hexosamine biosynthetic pathway and the corresponding
increase in intracellular glycosylation of proteins via O-linked β-N -acetylglucosamine (O-
GlcNAc) is sufficient to induce insulin resistance (IR) in multiple systems. Previously, our
group used shotgun proteomics to identify multiple rodent adipocytokines and secreted
proteins whose levels are modulated upon the induction of IR by indirectly and directly
modulating O-GlcNAc levels. We have validated the relative levels of several of these fac-
tors using immunoblotting. Since adipocytokines levels are regulated primarily at the level
of transcription and O-GlcNAc alters the function of many transcription factors, we hypoth-
esized that elevated O-GlcNAc levels on key transcription factors are modulating secreted
protein expression. Here, we show that upon the elevation of O-GlcNAc levels and the
induction of IR in mature 3T3-F442a adipocytes, the transcript levels of multiple secreted
proteins reflect the modulation observed at the protein level. We validate the transcript
levels in male mouse models of diabetes. Using inguinal fat pads from the severely IR
db/db mouse model and the mildly IR diet-induced mouse model, we have confirmed that
the secreted proteins regulated by O-GlcNAc modulation in cell culture are likewise mod-
ulated in the whole animal upon a shift to IR. By comparing the promoters of similarly
regulated genes, we determine that Sp1 is a common cis-acting element. Furthermore,
we show that the LPL and SPARC promoters are enriched for Sp1 and O-GlcNAc modi-
fied proteins during insulin resistance in adipocytes. Thus, the O-GlcNAc modification of
proteins bound to promoters, including Sp1, is linked to adipocytokine transcription during
insulin resistance.
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INTRODUCTION
It is estimated that diabetes affects 8.3% of the United States pop-
ulation (1). Type 2 diabetes mellitus (T2DM) is characterized
by both hyperinsulemia and hyperglycemia, which result from
a combination of whole-body insulin resistance and pancreatic
beta-cell dysfunction that leads to insulin insufficiency (2). T2DM
can lead to a wide-range of severe and costly complications, such
as blindness, kidney failure, stroke, and cardiovascular disease (3).
The abundance of associated complications reflects the number of
interrelated systems involved in T2DM pathogenesis (4).
White adipose tissue is an important mediator of energy home-
ostasis. In addition to its role as an energy storage depot, it acts
as an endocrine organ by secreting adipocytokines, such as leptin
and adiponectin. Adipocytokines can affect both local and distant
tissue insulin sensitivity and energy homeostasis (5, 6). Obesity
alters the ability of adipose tissue to properly express and secrete
adipocytokines. Obesity, which affects more than 10% of adults
world-wide, is the leading environmental risk factor for the devel-
opment insulin resistance and T2DM (7–9). Importantly, several
adipocytokines have been implicated in the development of insulin
resistance and the pathogenesis of T2DM (10). The mechanism by
which adipocytes respond to the excess nutrient-flux during obe-
sity and insulin resistance and alter the secretion of adipocytokines
is not completely understood.
One way for cells to sense nutrient abundance and thereby alter
their metabolism and gene expression is through the hexosamine
biosynthetic pathway (HBP). In 1991, Marshall et al. first impli-
cated the HBP in the development of insulin resistance (11). The
HBP has been proposed to be a nutrient-flux sensor, since it utilizes
2–5% of intracellular glucose, and acts to limit the amount of glu-
cose uptake by inducing insulin resistance (11). The end product
of the HBP, uridine 5′-diphospho-N -acetylglucosamine (UDP-
GlcNAc), is the sugar donor for the enzyme O-GlcNAc trans-
ferase (OGT), which transfers the O-GlcNAc post-translational
modification onto serine or threonine residues of nuclear and
cytoplasmic proteins (12–15). It has been demonstrated by many
groups, including our own, that in multiple systems the eleva-
tion of O-GlcNAc levels is sufficient to induce insulin resistance
(16–21).
The expression of several adipocytokines has been shown to
be regulated at the level of transcription (22–26). Additionally, the
transcription and secretion of several adipocytokines is modulated
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by altered HBP flux (22, 27, 28). Transgenic mice overexpressing
OGT in peripheral tissues have both glucose disposal defects and
hyperleptinemia, suggesting that the O-GlcNAc modification is
intricately tied to the development of insulin resistance and the
regulation of adipocytokines (16).
We have recently used shotgun proteomics to identify multiple
murine secreted proteins from adipocytes (adipocytokines) whose
levels are modulated upon the induction of insulin resistance by
indirectly and directly modulating O-GlcNAc levels (29). In this
study, we investigate the transcriptional regulation of several of
the secreted proteins identified by proteomics. We explore whether
O-GlcNAc modified transcription factors are regulating these pro-
teins, since several adipocytokines are known to be regulated at
the level of transcription and O-GlcNAc has been demonstrated
to modify and alter the function of many transcription factors (30,
31). Here, we show that these secreted factors are co-regulated in a
mouse adipocyte cell line and two mouse models of insulin resis-
tance. We demonstrate that the promoters of these genes contain a
common cis-acting motif for Sp1. We determine that Sp1 is more
heavily O-GlcNAc modified during insulin resistance. Finally, we
determine that Sp1 and O-GlcNAc modified proteins are enriched
on the LPL and SPARC promoters. Our findings suggest that
the O-GlcNAc modification of proteins regulates adipocytokine
transcription during chronic insulin resistance.
MATERIALS AND METHODS
MATERIALS AND REAGENTS
Tissue culture media, serum, and antibiotics were pur-
chased from Gibco (Grand Island, NY, USA). 3-isobutyl-1-
methyxanthine and dexamethasone were from Sigma (St. Louis,
MO, USA). Recombinant insulin, human, was from Roche
Diagnostics (Indianapolis, IN, USA). O-(2-acetamido-2-deoxy-
d-glucopyranosylidene)amino N -phenyl carbamate (PUGNAc)
was from Toronto Research Chemicals Inc. (North York, ON,
USA). GlcNAcstatin was a kind gift from Dr. Daan van Aal-
ten (University of Dundee, Dundee, Scotland). Anti-Sp1 (PEP
2), anti-LPL (H-53), anti-Angiotensin I/II (N-10), anti-ERK-2
(C-14), normal sera, and agarose conjugated beads were from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-PEBP1
was from Novus Biologicals (Littleton, CO, USA). Anti-SPARC
was from Abcam (Cambridge, MA, USA). Anti-O-GlcNAc (RL2)
was from Enzo Life Sciences (Farmingdale, NY, USA). Anti-O-
GlcNAC (CTD110.6) was previously generated in Dr. Gerald W.
Hart’s Laboratory (Johns Hopkins University, Baltimore, MD,
USA). Dynabead Protein G was from Life Technologies (Carlsbad,
CA, USA).
CELL CULTURE AND TREATMENTS
3T3-F442a preadipocytes were maintained and differentiated as
previously described (29, 32). On day 6 after the induction of dif-
ferentiation, the adipocytes were maintained in the appropriate
low (1.0 g/L) or high glucose (4.5g/L) DMEM media contain-
ing 10% FBS, antibiotics, and vitamins with or without 100µM
PUGNAc, 20 nM GlcNAcstatin, or 100 nM insulin. After 24 h incu-
bation, cells were washed either three times or five times (for media
immunoblotting) with low or high glucose serum free media
without antibiotics and vitamins. Following the rinses, cells were
incubated for 16 h in the appropriate low or high glucose media
without serum, antibiotics, and vitamins and with or without
100µM PUGNAc, 20 nM GlcNAcstatin, or 1 nM insulin. After the
incubation, the conditioned media was carefully collected, filtered,
and buffer exchanged as previously described (29). The remaining
cells were washed two times with ice cold PBS and then harvested
by scraping and stored at−80°C until further analysis.
ANIMALS
Animal procedures were approved by the Institutional Animal
Care and Use Committee of the University of Georgia. Animals
were group housed with a 12-h light, 12-h dark cycle. Inguinal
and retroperitoneal fat tissues from 12-week-old-male C57BL/6J
wt (wt), C57BL/6J db/db (6J), and C57BL/3J db/db (3J) mice were
isolated along with serum. Mice were fed ad libitum normal rodent
chow. After sacrifice by decapitation, the inguinal fat was weighed,
snap frozen, and stored at−80°C until transcript analysis. Both the
3J and 6J mice had both inguinal and retroperitoneal fat masses
three times greater than the wildtype littermates as well as elevated
serum glucose levels (>1.5×) and insulin levels (>5×) with the
3J mice having higher levels than 6J mice. For the diet-induced
insulin resistance experiment, young (~9 weeks) C57BL/6 male
mice were purchased from The Jackson Laboratory (Bar Harbor,
ME, USA). Both treatment groups were fed ad libitum normal
rodent chow and water. The mice in the high fat high sucrose
(HFHS) treatment group were given free access to a 30% sucrose
solution and lard in addition to their normal chow and water.
After week 1, 2, and 3 of treatment, an insulin sensitivity test (ITT)
was performed on a pair of mice closest to the average weight of
each treatment group. The insulin sensitivity test was performed
as previously described (33). Weights were recorded every week.
After 3 weeks of treatment, six mice from each treatment group
were sacrificed by decapitation. Trunk blood was collected for the
measurement of serum insulin using a LINCO rat insulin RIA kit
(EMD Millipore Corporation, Billerica, MA, USA). The liver and
four fat pads (inguinal, epididymal, mesenteric, and retroperi-
toneal) were weighed, snap frozen, and stored at −80°C until
transcript analysis.
CELL LYSATES, WESTERN BLOTTING, AND IMMUNOPRECIPITATION
For immunoprecipitations and anti-O-GlcNAc Western blots,
3T3-F442a cell pellets were lysed in 20 mM Tris pH 7.5, 150 mM
NaCl, 1 mM EDTA, 1% NP-40, 1:100 protease inhibitor cocktail
set V, EDTA-free (Calbiochem), and 1µM PUGNAc. Protein con-
centration was determined using the Pierce BCA Protein Assay Kit
(Thermo Scientific, Rockford, IL, USA). The CTD110.6 Western
blots were performed essentially as described (34). Immunopre-
cipitations were carried out at 4°C overnight using anti-Sp1 or nor-
mal rabbit IgG with 750µg of precleared protein lysate. Immuno-
complexes were collected using Protein A/G-PLUS agarose beads
for 2 h. Beads were washed four times with a modified RIPA buffer
(20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40,
0.1% SDS) and one time with a high salt modified RIPA buffer
(same as above except 500 mM NaCl). Proteins were eluted by
boiling beads in 1× laemmli buffer and then transferred to a fresh
tube for Western blotting. For the concentrated media Western
blots, the protein concentration of the concentrated 3T3-F442a
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media was determined using the Bradford method and verified
by Coomassie staining. Equal amounts of protein were separated
by SDS-PAGE with Tris–HCl precast minigels (Bio-Rad, Her-
cules, CA, USA) and transferred to poly(vinylidene difluoride)
(PVDF) membranes (for concentrated media) or nitrocellulose
membranes (for immunoprecipitations) for Western blot analysis.
After blocking for at least 1 h, membranes were incubated with the
appropriate primary antibody overnight at 4°C. Membranes were
incubated with the appropriate horseradish peroxidase-coupled
secondary antibodies for 1 h, followed by extensive washing and
Pierce ECL detection. ImageJ was used for densitometry (35).
CHROMATIN IMMUNOPRECIPITATION
Chromatin Immunoprecipitations were performed as in the Milli-
pore EZ-ChIP kit with some modifications. Day 8 adipocytes were
washed once with room temperature PBS and then crosslinked
by adding 1% formaldehyde in PBS and incubating for 10 min.
The adipocytes were washed three times with cold PBS and then
harvested by scraping. The adipocytes were resuspended in hypo-
tonic lysis buffer (20 mM Tris–HCl, pH 7.5, 10 mM NaCl, 3 mM
MgCl2, 1:100 Calbiochem protease inhibitor) and incubated on
ice then dounce homogenized. The nuclei were collected by cen-
trifugation and then resuspended in SDS lysis buffer. DNA was
sheared to between 200 and 1000 base pair fragments using a Mis-
onix S-4000 sonicator. Protein concentration was quantified using
the Pierce BCA Protein Assay Kit. One hundred micrograms of
chromatin was used per immunoprecipitation. Sonicated chro-
matin was diluted 1:10 with dilution buffer and precleared using
Protein A/G-PLUS agarose, normal goat IgG, and sheared salmon
sperm DNA (ssDNA) (Ambion). Three percent of the sample was
saved as Input. One microgram of anti-Sp1, anti-O-GlcNAc (RL2),
or normal IgG was used for the immunoprecipitation. Immuno-
complexes were collected for 1 h using Protein G Dynabeads that
were blocked with ssDNA and BSA (New England Biolabs). The
Dynabeads were washed five times and then eluted with 1% SDS
and 0.1 M NaHCO3. The elutions were decrosslinked at 65°C
overnight with NaCl and RNase A (Ambion). After Proteinase
K treatment (New England Biolabs), samples were purified by a
Phenol–Chloroform extraction followed by ethanol precipitation
overnight at−20°C using glycogen as a carrier. Precipitated DNA
was resuspended in 3 mM Tris–HCl pH 8.0, 0.1 mM EDTA. qPCR
was performed using primers for the proximal mouse SPARC
and LPL promoter Sp1-binding sites. Sequences of primers were
SPARC primers 5’-AGGCAAGTTCACTCGCTGGCT-3’(forward)
and 5’-AGACACCCTGGCCCCACCTG-3’ (reverse) and LPL
primers 5’-CCTTCTTCTCGCTGGCACCGTT-3’ (forward) and
5’-GGGCAGAACAGTTACAAGGGGCA-3’ (reverse). The fold
enrichment was calculated for each primer/antibody/treatment
combination. First the normalized ChIP C t values were calcu-
lated: ∆C t(normalized ChIP)= {C t(ChIP)− [C t(Input)− Log2 (Input
Dilution Factor)]}. The % Input was calculated: % Input= 2
(−∆Ct [normalized ChIP]). Lastly, fold enrichment was calculated: fold
Enrichment= (% Input of antibody/% Input of IgG).
GENE EXPRESSION ANALYSIS
RNA was isolated from 3T3-F442a cell pellets and inguinal fat pads
using the Invitrogen PureLink Micro-to-Midi RNA Total RNA
Purification System with Trizol reagent and on column DNase I
treatment. The Invitrogen Superscript III First-Strand Synthesis
System for RT-PCR was used to synthesize cDNA (Life Technolo-
gies, Carlsbad, CA, USA). All RT-qPCR primers were obtained
from Qiagen QuantiTect Primer Assays and used with Qiagen
QuantiTect SYBR Green PCR Kits (Qiagen, Valencia, CA, USA).
ChIP-qPCR primers were used with iQ SYBR Green Supermix
(Bio-Rad, Hercules, CA, USA). Amplifications were performed
in a Bio-Rad 96-well iCycler or myIQ real-time detection system
using the appropriate QuantiTect or iQ SYBR Green cycling pro-
tocol. Changes in target gene expression were normalized to TATA
box binding protein (Tbp) and ribosomal protein L4 expression
(Rpl4). Relative transcript levels were calculated using the ∆∆Ct
method (36). Normoglycemic transcript levels were set to 100.
MOTIF ANALYSIS
Promoter sequences containing 500 bp upstream of the transcrip-
tional start site were collected for human, mouse, and rat using
the UCSC Genome Browser (37). No rat ortholog was found for
Quiescin Q6. The human set was used as the main set and was sup-
ported by the mouse and rat ortholog sets. Three genes that were
identified in the rodent adipocyte secretome but did not change in
expression during insulin resistance were used as the negative set
for human, mouse, and rat (29). Seven motif finding tools were
used for primary motif finding: AlignACE (38), Bioprospecter
(39), CONSENSUS(40), CUBIC (41), MDscan (42), MEME (43),
and BOBRO (44). For each candidate, a position weight matrix
and scoring matrix were generated (Table S1 in Supplementary
Material). Corresponding transcription factor binding motifs were
determined by analyzing the position weight matrix with TOM-
TOM (45). Conserved transcription factor binding motifs were
confirmed using human and mouse sequences in rVISTA 2.0 (46).
STATISTICAL ANALYSIS
All statistics were performed using the General Linear Model
Analysis of Variance [GLM AOV, Statistix (Statistix 10.0, 2010,
Tallahassee, FL, USA)]. Error bars represent the SEM of indepen-
dent experiments. P-values under 0.05 were considered significant
and represented using an * in all figures. All experiments shown
were replicated three to five times.
RESULTS
THE INDUCTION OF INSULIN RESISTANCE IN 3T3-F442a ADIPOCYTES
MODULATES SECRETED STEADY-STATE PROTEIN LEVELS AND
TRANSCRIPT LEVELS IN THE SAME MANNER
3T3-F442a preadipocytes were differentiated into mature
adipocytes before experimental treatments. Mature adipocytes
were either maintained in insulin sensitive conditions [low glu-
cose (LG)] or shifted to insulin resistant conditions by the classical
treatment of high glucose and chronic insulin (HG+ INS) to gen-
erate hyperglycemia and hyperinsulemia or by treatment with
low glucose and the OGA inhibitors PUGNAc (LG+PUGNAc)
or GlcNAcstatin (LG+GlcNAcstatin) to more specifically elevate
global O-GlcNAc levels. Figure 1A shows that all insulin resistant
conditions generated elevated global O-GlcNAc levels as evalu-
ated by immunoblotting with an O-GlcNAc specific antibody.
Previously, our group used shotgun proteomics to character-
ize the secreted proteome of rodent adipocytes and to identify
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FIGURE 1 | Insulin resistant 3T3-F442a adipocytes display altered
adipocytokine expression. (A) 3T3-F442a adipocytes were grown
under insulin responsive (LG) or insulin resistant (LG with PUGNAc, LG
with GlcNAcstatin, or HG with insulin) conditions as described in
Section “Materials and Methods.” Equal amounts of protein from
whole cell lysates were separated by SDS-PAGE and Western blotting
was performed using anti-O-GlcNAc (CTD110.6). Equal loading was
confirmed by Western blotting with ERK2. (B) A partial list of rodent
adipocytokines found to be regulated by insulin resistance based on
proteomic quantification. +Indicates that the protein expression is
upregulated upon the induction of insulin resistance. (C) Proteomic
quantification of protein expression was confirmed by Western blotting
in 3T3-F442a adipocytes. Equal amounts of concentrated media were
separated by SDS-PAGE and Western blotting was performed with the
designated antibodies. (D) The steady-state transcript levels were
evaluated using qPCR in 3T3-F442a adipocytes. Data are presented so
that 100% represents the transcript level in the insulin responsive
condition (LG). *P <0.05.
multiple proteins whose levels are modulated upon the induc-
tion of insulin resistance by indirectly and directly modulating
O-GlcNAc levels in rodent adipocytes as described above (29).
Figure 1B shows a shortened list of adipocytokines whose protein
expression was found to be positively regulated by the induc-
tion of insulin resistance using quantitative proteomics in our
previous studies. Here, we validated the relative levels of several
of these secreted proteins using immunoblotting as an orthogo-
nal method. 3T3-F442a adipocyte conditioned media from each
treatment group was concentrated and buffer exchanged before
immunoblotting with selected antibodies. Figure 1C shows that
the regulation observed by quantitative proteomics is recapitulated
by immunoblotting as an independent method. Since adipocyte
insulin resistance was induced by either indirectly (HG+ INS) or
directly (LG+PUGNAc) altering O-GlcNAc levels, it is likely that
O-GlcNAc is modulating the secretion of these adipocytokines.
Since the secretion of many of the adipocytokines studied thus far
is regulated at the level of transcription (22–26) and O-GlcNAc has
been shown to modify and alter the function of many transcription
factors (47), we hypothesized that the elevation of O-GlcNAc lev-
els was regulating many of the identified adipocytokines at the
level of transcription. Figure 1D shows that upon the elevation
of O-GlcNAc levels and the induction of insulin resistance in
3T3-F442a adipocytes, the steady-state transcript levels of many
of the identified secreted proteins, as measured by qPCR, reflect
the modulation observed at the protein level.
THE INDUCTION OF INSULIN RESISTANCE MODULATES SECRETED
PROTEIN STEADY-STATE TRANSCRIPT LEVELS IN A GENETIC INSULIN
RESISTANT MOUSE MODEL
The mouse preadipocyte cell lines are a very useful system for
studying adipocyte biology; however, their ability to secrete pro-
teins at the high levels measured in vivo is impaired in many cases
(48). Additionally, the complex paracrine interactions between
adipocytes and the stromal-vascular cell fraction that comprises
adipose tissue as well as the signaling between tissues in a whole
animal are lost in adipocyte cell lines in vitro (49). Therefore, the
regulation of adipocytokine transcript levels upon the induction of
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insulin resistance was examined in a biologically relevant mouse
model. The inguinal fat pads from severely insulin resistant 12-
week-old male leptin receptor mutant (db/db) mice were used for
transcript analysis. db/db mice produce leptin but fail to respond
to it. The C57BL/6J db/db (6J) mice produce only the short-form
leptin receptors (Ob-Ra, Ob-Rc, Ob-Rd) and the circulating form
leptin receptor (Ob-Re) but not the long signaling form of the
receptor (Ob-Rb). The C57BL/3J db/db (3J) mice produce only the
circulating form leptin receptor (Ob-Re) (50). Figure 2 shows the
inguinal fat pad transcript levels in the db/db mouse models vary
significantly from the wt mice and reflect the modulation shown
at the transcript and protein levels in the 3T3-F442a adipocytes.
All of the transcripts were elevated with the exception of the con-
trol gene, adipsin. Adipsin transcript levels have been shown to be
downregulated in many models of rodent obesity (51).
THE INDUCTION OF INSULIN RESISTANCE MODULATES STEADY-STATE
TRANSCRIPT LEVELS IN A DIET-INDUCED IR MOUSE MODEL
Evidence suggests that T2DM develops from a combination of
genetic and environmental factors but the relative contribution of
each is unclear (52). A monogenic genetic mouse model (db/db)
does not represent the true genetic heterogeneity that is present in
most cases of human T2DM (53). In addition, the genetic defect
is in an adipocytokine pathway, which could lead to potentially
confounding effects for this experiment (54). To address these con-
cerns, a diet-induced insulin resistant mouse model was developed
by feeding ad libitum sucrose and lard (HFHS) to approximately
9-week-old C57BL/6 mice as described in Section “Materials and
Methods.” After 3 weeks of treatment, the live weight as well as the
wet weight of the inguinal, epididymal, mesenteric, and retroperi-
toneal fat pads was significantly increased in the HFHS mice
compared to the mice on the normal chow diet (Figure S1A in
Supplementary Material). The mice on the HFHS diet had ele-
vated glucose levels and an attenuated response to insulin (Figure
S1B in Supplementary Material). In addition, the mice displayed
significantly elevated insulin levels (Figure S1C in Supplementary
Material). After 3 weeks on the HFHS diet, the mice displayed
mild insulin resistance and obesity so the inguinal fat pads were
used for transcript analysis. Since the diet-induced insulin resis-
tant mice were mildly obese and insulin resistant, we would expect
the adipsin levels to only change slightly in contrast to the db/db
mice, which were extremely obese and insulin resistant. Figure 3
shows the transcript levels were significantly elevated in the HFHS
mice inguinal fat pads for all genes excluding adipsin. The diet-
induced insulin resistant mice transcript levels reflect the modula-
tion shown at the transcript level in the db/db mouse fat pads and
at the transcript and protein levels in the 3T3-F442a adipocytes.
Table 1 shows the relative increase in transcript levels in the insulin
resistant mice (HFHS and 6J) compared to the transcript levels of
the insulin sensitive mice (N and wt), which are set to 100%.
Given that transcript level regulation is consistent for both insulin
resistant mouse models, the transcript regulation observed in cell
culture during insulin resistance is validated.
SP1 IS A COMMON CIS-ACTING ELEMENT FOR THE ADIPOCYTOKINE
PROMOTERS AND THE O-GLcNAc MODIFICATION OF SP1 IS ALTERED
DURING INSULIN RESISTANCE
We hypothesized that a common transcription factor or cofactor
was responding to the elevation of O-GlcNAc levels and alter-
ing the transcription of the observed secreted proteins. Multiple
complementary motif finding programs were used to analyze the
same set of orthologous proximal promoters in order to find a
more accurate set of regulatory motifs. Human, mouse, and rat
promoters were used to identify conserved motifs, with the hope
FIGURE 2 | Genetic insulin resistant mice display altered adipocytokine steady-state transcript levels. Inguinal fat pads from 12-week-old male wt, 6J,
and 3J (n=6) mice were used for transcript analysis by qPCR. Data are presented so that 100% represents the transcript level in the insulin responsive
condition (wt ). *P <0.03.
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FIGURE 3 | Diet-induced insulin resistant mice display altered
adipocytokine steady-state transcript levels. Inguinal fat pads from
C57BL/6 mice fed normal chow (N) (n= 4) or a high fat, high sucrose (HFHS)
(n=3) diet for 3 weeks were used for transcript analysis by qPCR. Data are
presented so that 100% represents the transcript level in the insulin
responsive condition (N). *P <0.05.
Table 1 | Secreted protein transcript levels elevated in mouse models
of insulin resistance.
Mouse model LPL SPARC Cathepsin B Serpin A Quiescin Q6
Insulin sensitive 100 100 100 100 100
Diet-induced 185 224 146 139 237
Genetic 316 511 379 760 425
that the most important regulatory motifs would be under
stronger evolutionary pressure (Figure 4A) (55). Twenty-four
common putative regulatory motifs were identified using motif
analysis programs as described in Section“Materials and Methods”
(Table S1 in Supplementary Material). The putative regulatory
motifs were compared to known transcription factor binding
motifs. The Sp1-binding motif was found to match putative reg-
ulatory motif 3 (Figure 4B). The conservation of the Sp1 sites
between human and mouse promoters was verified using rVista
2.0. Sp1 is relevant to adipocytokine transcription since it is a tar-
get of the insulin signaling cascade and many promoters of genes
regulated during insulin resistance have Sp1 motifs (56–61). In
addition, Sp1 is known to be dynamically modified by O-GlcNAc
(47). Sp1 O-glycosylation is reported to be elevated in the liver,
kidney, and adipose tissue of db/db mice (62). Many studies have
associated the altered O-GlcNAc modification of Sp1 with altered
transcriptional activation of target genes (63–68). Figure 4C shows
that immunoprecipitated Sp1 has greater O-GlcNAc modification
during insulin resistance in 3T3-F442a adipocytes. Both direct
(LG+GlcNAcstatin) and indirect (HG+ INS) modulation of O-
GlcNAc levels trended toward elevated Sp1 O-GlcNAc modifica-
tion although only the GlcNAcstatin reached statistical signifcance.
The more modest O-GlcNAc modification seen in the HG+ INS
condition was most likely due to the more modest increase in
global O-GlcNAc levels (Figure 1A).
SP1 AND O-GLcNAc MODIFIED PROTEINS ARE ENRICHED ON THE
PROXIMAL SPARC AND LPL PROMOTERS DURING INSULIN
RESISTANCE
We noticed that two of the identified motif three positions on the
promoters corresponded with known biologically relevant Sp1-
binding sites for LPL and SPARC. Since these sites are reported to
be important for transcriptional activation, we wanted to deter-
mine whether Sp1 and O-GlcNAc modified proteins were enriched
at these sites during insulin resistance in 3T3-F442a adipocytes.
ChIP was performed with Sp1 and O-GlcNAc specific antibod-
ies. Enrichment on the promoters was determined by analyzing
purified DNA using qPCR with primers designed to amplify the
region containing the Sp1-binding motif on either the LPL or
SPARC promoter. Figure 5 shows both of the promoter regions
showed significant enrichment of both Sp1 and O-GlcNAc mod-
ified proteins during insulin resistant conditions. These results
suggest that the elevation of global O-GlcNAc levels, either directly
or indirectly, leads to increased O-GlcNAc modification of Sp1
and increased Sp1 enrichment on the SPARC and LPL proximal
promoters. Since the O-GlcNAc antibody will bind any protein
modified with O-GlcNAc, the enrichment of O-GlcNAc on the
LPL and SPARC promoters could be due to O-GlcNAc modified
Sp1 or potentially other O-GlcNAc modified proteins.
DISCUSSION
White adipose tissue plays an important role in maintaining energy
homeostatis by mediating lipid flux and altering the secretion of
adipocytokines. Adipocytokines can act in an autocrine, paracrine,
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FIGURE 4 | An O-GlcNAc modified protein is identified as a common
regulatory element. (A) The promoters of target co-regulated genes for
human, mouse, and rat were analyzed for common regulatory motifs as
described in Section “Materials and Methods.” Three genes that were not
co-regulated were used as a negative set to avoid identifying non-regulatory
motifs. *Denotes no orthologous gene in rat. (B) TOMTOM was used to
assign identified regulatory motifs to known transcription factor binding
motifs. Regulatory motif 3 matches the Sp1 DNA binding motif with a p-value
of 1.3×10−6. (C) Whole cell lysates from insulin responsive and insulin
resistant 3T3-F442a adipocytes were subjected to immunoprecipitation with
anti-Sp1 or normal rabbit IgG followed by immunoblotting with anti-Sp1 or
anti-O-GlcNAc (RL2). A representative immunoblot is shown (right panel ). The
ratio of O-GlcNAc modified Sp1 to total Sp1 was quantified using
densitometry of independent experiments (N =4).
or endocrine manner to regulate a variety of processes, including
energy homeostasis (5). Genetic mouse models showing that the
induction of insulin resistance in white adipose tissue induces
whole-body insulin resistance have highlighted the importance
of adipocytokines during insulin resistance (69–71). In addition,
adipocytokines are implicated in many of the complications lead-
ing to and resulting from T2DM, especially the tissue remodeling
during nephropathy, cardiovascular disease, and obesity (72).
Many of the secreted proteins we studied are extracellular
matrix (ECM) modulators and associated with inflammatory
states. SPARC is a modulator of cell – ECM interactions and has
diverse roles in osteogenesis, angiogenesis, fibrosis, tumorigenesis,
and adipogenesis (73). Cathepsin B is associated with ECM degra-
dation, apoptosis, and inflammation (74). SerpinA is an acute
phase response protein that is involved in inflammation (75). Qui-
escin Q6 is upregulated in pancreatic cancer and may promote
tumor cell invasion by upregulating matrix metalloproteinases
(76, 77). Involvement in tumorigenesis is another common theme
for these adipocytokines. During obesity, extensive remodeling is
required for the expansion of fat pads (78). These ECM modula-
tors may play an important role in local tissue remodeling. Obese
adipose tissue is associated with an inflammatory response, which
may also be mediated in part by these adipocytokines (78–83).
In this study, we have attempted to better define the relationship
between O-GlcNAc modification and adipocyte-secreted protein
transcription during insulin resistance. Several studies have sug-
gested that leptin and adiponectin are regulated primarily at the
level of transcription in adipocytes (22–25, 84). We investigated
whether the secreted factors that we identified by quantitative
proteomics were similarly regulated after confirming the eleva-
tion via an orthogonal method, Western blotting, for several of
these secreted proteins. We have also recently evaluated many of
these secreted factors in human adipose tissue with similar find-
ings (85). We found that the induction of insulin resistance in
mouse adipocytes elevated transcript levels in the same manner
as protein levels for several of the secreted proteins identified by
proteomics (Figure 1). Although a role for the transcriptional reg-
ulation of adipocytokine secretion has been established for SPARC
(86), there are conflicting reports for LPL (87–90), and it was
not known whether Cathepsin B, Quiescin Q6, and SerpinA were
transcriptionally regulated in adipocytes. In addition, the biolog-
ical relevance of the transcriptional upregulation of the proteins
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FIGURE 5 | ChIP analysis of conserved Sp1 sites on the SPARC and LPL
promoters. Insulin responsive and insulin resistant 3T3-F442a adipocytes
were subjected to chromatin immunoprecipitation with anti-Sp1,
anti-O-GlcNAc (RL2), or normal IgG. Quantitative PCR was performed with
primers designed to amplify the conserved Sp1-binding site motif on the
LPL (A) or SPARC (B) promoter. Fold enrichment was calculated using%
Input as described in Section “Materials and Methods.” *P <0.05.
during insulin resistance was verified using both a genetic and
diet-induced mouse model of insulin resistance (Figures 2 and 3).
Several studies have suggested that adipocytokine expression
is regulated by the HBP and O-GlcNAc. Infusions of metabolites
that increased HBP flux into rats increased leptin expression (22,
91). Both GFAT and OGT transgenic mice displayed hyperleptine-
mia (16, 27, 28). GFAT transgenic mice also displayed decreased
adiponectin levels (28). In primary human adipocytes and 3T3-
L1 mouse adipocytes, HBP flux was shown to correlate with leptin
expression (27, 92). Although many studies have manipulated the
HBP, studies that manipulate O-GlcNAc levels more directly and
examine adipocytokine expression have been lacking. We found
that both the direct modulation of O-GlcNAc levels by the addi-
tion of OGA inhibitors and the indirect modulation of O-GlcNAc
levels by hyperglycemia and chronic hyperinsulinemia in mouse
adipocytes elevated transcript levels in the same manner as pro-
tein levels (Figure 1). It was not known whether inducing insulin
resistance solely by raising global O-GlcNAc levels would regulate
these secreted proteins at the level of transcription.
It is reasonable to assume that co-regulated genes have a similar
upstream regulator. Since we found that the expression of these
proteins was similarly regulated by both classical insulin resistance
and by solely raising global O-GlcNAc levels, we hypothesized that
O-GlcNAc was a regulator. O-GlcNAc has been proposed to be a
“nutrient sensor” because the levels of the end product of the HBP,
UDP-GlcNAc, are regulated by the flux of glucose, uridine, gluta-
mine, and FFA’s (93, 94). OGT is responsive to physiological levels
of UDP-GlcNAc, so increased HBP flux results in globally elevated
levels of O-GlcNAc modification (95). The regulation of OGT is
complex and still being elucidated but it is clear that it has a pref-
erence for certain proteins and sites and does not universally add
O-GlcNAc to all proteins (96–98). A large body of literature has
shown that the O-GlcNAc modification plays an important role in
transcriptional regulation. O-GlcNAc modifies transcription fac-
tors and cofactors, RNA Pol II, chromatin remodelers, and has
even been identified as part of the histone code. O-GlcNAc mod-
ification of proteins can affect protein stability, protein–protein
interactions, chromatin remodeling, transcriptional initiation and
elongation, DNA binding, and localization (47, 99).
The secreted factors were regulated at the level of transcription,
so we looked for common transcription factor binding motifs.
After determining that Sp1 was a common cis-acting motif for
these genes, we found that the O-GlcNAc modification of Sp1
trended toward an increased level during insulin resistance in
mouse adipocytes (Figure 4). Sp1 has been implicated in the tran-
scriptional regulation of LPL, SPARC, Cathepsin B, and SerpinA.
A role for Sp1 as a regulator of SPARC transcription has been
established in transformed cells. The proximal promoter of SPARC
contains several modified GC-boxes that are binding sites for Sp1
and/or Sp3. Sp1 and/or Sp3 are required for SPARC transcriptional
activation in chickens, mice, and human beings (100–102). In
chick embryonic fibroblasts, v-Jun represses SPARC promoter acti-
vation and initiates cell transformation by targeting the minimal
promoter region. It was shown that v-Jun does not bind this DNA
region directly but binds Sp1 and/or Sp3 to target promoter activa-
tion (101). c-Jun activates SPARC transcription in human MCF7
cells through the activation of Sp1 (100). In mammary carcinoma,
Brg-1, a SWI/SNF chromatin remodeling complex ATPase, was
shown to interact with Sp1 to activate SPARC transcription (102).
Sp1’s involvement in SPARC transcription in adipocytes has not
previously been described.
Several studies have associated Sp1 and/or Sp3 with LPL tran-
scriptional regulation. Interferon-γ (IFNγ) decreases macrophage
LPL transcription by decreasing Sp3 protein levels and Sp1 DNA
binding to sites in the 5′ UTR, which is mediate by casein kinase
2 (CK2) and Akt (103, 104). Transforming growth factor-β (TGF-
β) represses macrophage LPL transcription through Sp1 and/or
Sp3 sites in the 5′-UTR (105). Sp1 and/or Sp3 also bind an
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evolutionarily conserved CT element (−91 to−83), also known as
a GA box, in the proximal promoter. Sterols regulate LPL through a
SRE site that is close to the CT element (89, 106). A T(−93)G SNP
that is close to the CT element has been associated with a predis-
position to obesity and familial combined hyperlipidemia in some
studies in human beings. The minor allelic frequency is highly
variable for difference ethnic populations and the SNP effect may
be influenced by the synergistic effects of a Asp9Asn and T(-93)G
haplotype that is present in some populations (107–110). People
with both the Asp9Asn and T(-93)G mutations have been shown
to have an increased risk of cardiac disease and decreased LPL
activity in some studies (111–113). In the South African black
population, the SNP was associated with mildly lower triglyc-
eride levels and was associated with higher promoter activation
in smooth muscle cells (108, 114). This is in contrast to other
studies, which show that the mutation decreases Sp1 and/or Sp3
DNA binding leading to lowered transcriptional activation (106,
107, 109, 110). Sterol regulatory element-binding protein (SREBP)
was found to act synergistically with Sp1 to activate the promoter
in macrophages. Mutation of the CT element is also reported to
decrease promoter reporter activity in 3T3-F442a pre-adipocytes
(115). The importance of these Sp1/Sp3 binding sites has not been
previously explored in mature adipocytes.
Both Sp1 and O-GlcNAc modified proteins were found to be
significantly enriched in the region of the conserved Sp1 site on
both the LPL and SPARC promoters (Figure 5). In our experi-
ments in mature mouse adipocytes, Sp1 is most likely facilitating
transcriptional activation. The studies described above have begun
to shed light on the role of O-GlcNAc in modulating adipocytokine
transcription through the modification of Sp1. Although Sp1 in
ubiquitously expressed and often thought of as a housekeeping
transcription factor, the diversity of Sp1 post-translational modi-
fications and the wide-range of interaction partners can fine tune
Sp1 activity in a context specific manner (116). Sp1 is subject to
many forms of post-translational modification including phos-
phorylation, acetylation, sumoylation, ubiquitylation, and glyco-
sylation. The sites of phosphorylation on Sp1 can either increase
or decrease Sp1 DNA binding and transcriptional activation (117).
Glycosylation can affect Sp1 stability, protein–protein interactions,
DNA binding, degree of phosphorylation, and localization (47).
These other modifications as well as the recruitment of other
proteins to the promoters may explain the differences between
HG+ INS and LG+GNS. Sp1 has at least eight sites of O-GlcNAc
modification, but the specific roles of each site is still being eluci-
dated (118). Five sites of modification have been mapped to the
DNA binding domain, and the mutation of these sites can disrupt
Sp1 transcriptional activation in hepatocytes (62, 68). O-GlcNAc
modification of the Sp1 activation domain inhibits Sp1 transac-
tivation (64, 119). Since O-GlcNAc acts as a nutrient-flux sensor,
many studies manipulate the glycosylation of Sp1 by manipulating
nutrient flux. Studies using glycosylation site-specific Sp1 mutants
would help to clarify the specific role of O-GlcNAc modification;
however, determining the action of a specific glycosylation site
could be complicated by the complex interplay between phos-
phorylation and O-GlcNAc modification as well as the presence
of several other O-GlcNAc sites. In addition, site-specific Sp1
studies in adipocytes would be challenging since adipocytes are
notoriously difficult to transfect. Other O-GlcNAc modified pro-
teins could also be modulating the adipocytokine transcription
since the O-GlcNAc enrichment on the promoters could be due to
proteins other than Sp1. ChIP-reChIP would help to determine,
which proteins are in complex on the promoters.
In conclusion, these experiments serve to identify a possible
mechanism by which adipocytes respond to insulin resistance and
regulate the expression of adipocytokines. Future work is aimed at
identifying the specific function of the O-GlcNAc modification on
Sp1 during insulin resistance in adipocytes. In addition, the mech-
anism of adipocytokine transcriptional upregulation in animal
models should be investigated. Understanding the transcriptional
regulation of adipocytokines by O-GlcNAc may provide therapeu-
tic targets for normalizing the expression of adipocytokines during
obesity and T2DM.
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Figure S1 | Characterization of the diet-induced IR mouse model. (A) After
3 weeks on either the HFHS diet (n=6) or normal diet (n=6), mice were
weighed, sacrificed, and the liver and four fat pads were dissected and
weighed. Data are presented so that 100% represents the weight of the normal
diet mice. (B) Insulin sensitivity test was performed as in Section “Materials
and Methods.” (C) Trunk blood was used for an Insulin RIA. *P <0.05.
Table S1 | Common motifs for adipocytokine promoters.
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